Silver Ronald 4

What Happened
Ronald Silver, Principal Accounting Officer of Ironwood Pharmaceuticals (IRWD), was granted 163,934 restricted stock units (RSUs) on March 10, 2026. The Form 4 reports the acquisition as 163,934 shares at $0.00 per share (transaction code A), so no cash was paid at grant and the filing shows $0 as the reported acquisition cost. This is an equity award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-03-10; Form 4 filed: 2026-03-12 (filed within two business days of the grant).
• Type: Award/Grant (Code A) — 163,934 RSUs acquired at $0.00 per share (total reported cost $0).
• Shares owned after transaction: Not disclosed in the provided filing summary.
• Footnote: The RSU award vests 25% on each approximate anniversary of the grant (annual vesting over four years).
• No 10b5-1 plan, tax‑withholding, or sale coding noted in the provided details.

Context
Restricted stock units are a common form of equity compensation; they convert to actual shares only as they vest, so the grant itself is not an immediate purchase or sale. Because the award vests over four years (25% annually), the economic benefit to the insider is realized over time as vesting occurs. This type of filing documents compensation-related equity grants and should not be read as a short‑term market signal.